M&A Deal Summary |
|
|---|---|
| Date | 2025-04-30 |
| Target | Regulus Therapeutics |
| Sector | Life Science |
| Buyer(s) | Novartis |
| Deal Type | Merger |
| Deal Value | 800M USD |
| Advisor(s) | Evercore Group (Financial) Latham & Watkins (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 104,323 |
| Revenue | 46.7B USD (2023) |
Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 34 of 34 |
| Sector: Life Science M&A | 28 of 28 |
| Type: Merger M&A Deals | 2 of 2 |
| State: California M&A | 7 of 7 |
| Country: United States M&A | 26 of 26 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 10 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-02-26 |
Novartis - Natural Products and Genetic Strains Assets
Basel, Switzerland Novartis's Natural Products and Genetic Strains Assets offers cutting-edge biological solutions for farmers. |
Sell | - |
